Document is current
Any future updates will be listed below
-
Authors
Häussinger, Dieter https://orcid.org/0000-0002-5936-682X
Dhiman, Radha K. https://orcid.org/0000-0002-4107-8512
Felipo, Vicente https://orcid.org/0000-0003-3145-9538
Görg, Boris https://orcid.org/0000-0002-4630-9420
Jalan, Rajiv
Kircheis, Gerald https://orcid.org/0000-0001-7948-2900
Merli, Manuela https://orcid.org/0000-0003-3173-9767
Montagnese, Sara https://orcid.org/0000-0003-2800-9923
Romero-Gomez, Manuel https://orcid.org/0000-0001-8494-8947
Schnitzler, Alfons https://orcid.org/0000-0002-6414-7939
Taylor-Robinson, Simon D. https://orcid.org/0000-0002-8811-1834
Vilstrup, Hendrik
- License Information
-
More Information
Article History
Accepted: 12 May 2022
First Online: 23 June 2022
Competing interests
: D.H. and G.K. are members of the “Flicker Diagnostics GbR”. The S.M. group has received research funding from AlfaSigma S.p.a., Norgine Ltd., Merz Pharmaceuticals GmbH, Umecrine Cognition AB and Versantis AG. R.J. has research collaborations with Yaqrit Ltd. and Takeda. R.J. is the inventor of OPA, which has been patented by University College London and licensed to Mallinckrodt Pharma. He is also the founder of Yaqrit Ltd., a spin-out company from University College London, Cyberliver Ltd. and Hepyx Ltd. S.D.T.-R., B.G., M.R.-G., M.M., R.K.D., H.V., A.S. and V.F. declare no competing interests.
